Lantheus appoints Dr. Phuong Khanh Morrow to board, effective Feb 1, 2025

Lantheus Holdings, Inc.

Dr. Phuong Khanh Morrow appointed independent director effective Feb 1, 2025; board expands to 11.
Morrow is Head of Oncology TAU at Takeda, former CMO at CRISPR Therapeutics, and VP at Amgen.
Will receive $60k annual cash retainer, $7.5k STC fee, initial $100k equity grant (50% RSU, 50% options), and $400k annual equity.
Appointed to Science and Technology Committee; board now has 11 directors, 9 independent.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Phuong Khanh Morrow

Director

LNTH · Lantheus Holdings, Inc.

Effective: 2025-01-29
Filed: January 30, 2025, 6:59 PM ET

On January 29, 2025, the board of directors of Lantheus Holdings, Inc. (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Phuong Khanh (P.K.) Morrow, M.D., an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology, to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Phuong Khanh Morrow was appointed as Director at Lantheus Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 29, 2025, the board of directors of Lantheus Holdings, Inc. (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Phuong Khanh (P.K.) Morrow, M.D., an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology, to the Board.

View on SEC.gov

Lantheus Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-016381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.